Cos­mo spin­out Cas­sio­pea wins FDA ap­proval for new ac­ne drug

A small Swiss-list­ed biotech spin­out se­cured FDA ap­proval for their first drug, set­ting them up to com­pete in a crowd­ed mar­ket for ac­ne.

Cas­sio­pea re­ceived an okay for Win­le­vi, the drug that has been at the top of the com­pa­ny’s pipeline since the com­pa­ny spun out from the Swiss phar­ma Cos­mo in 2015. It will take a lit­tle bit longer to mar­ket, though, like­ly be­cause the com­pa­ny has lit­tle com­mer­cial in­fra­struc­ture so far.  The biotech said they plan to start ear­ly 2021. A price will be an­nounced in Q4, Reuters re­port­ed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.